272 related articles for article (PubMed ID: 22180676)
21. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
22. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
[TBL] [Abstract][Full Text] [Related]
23. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Yuan J; Gnjatic S; Li H; Powel S; Gallardo HF; Ritter E; Ku GY; Jungbluth AA; Segal NH; Rasalan TS; Manukian G; Xu Y; Roman RA; Terzulli SL; Heywood M; Pogoriler E; Ritter G; Old LJ; Allison JP; Wolchok JD
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20410-5. PubMed ID: 19074257
[TBL] [Abstract][Full Text] [Related]
24. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
Maio M; Di Giacomo AM; Robert C; Eggermont AM
Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic use of anti-CTLA-4 antibodies.
Blank CU; Enk A
Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
[TBL] [Abstract][Full Text] [Related]
26. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
28. Ipilimumab: a promising immunotherapy for melanoma.
Thumar JR; Kluger HM
Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
[TBL] [Abstract][Full Text] [Related]
29. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.
Lebbé C; Weber JS; Maio M; Neyns B; Harmankaya K; Hamid O; O'Day SJ; Konto C; Cykowski L; McHenry MB; Wolchok JD
Ann Oncol; 2014 Nov; 25(11):2277-2284. PubMed ID: 25210016
[TBL] [Abstract][Full Text] [Related]
30. Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.
Wang XY; Zuo D; Sarkar D; Fisher PB
Expert Opin Pharmacother; 2011 Dec; 12(17):2695-706. PubMed ID: 22077831
[TBL] [Abstract][Full Text] [Related]
31. [Antibody therapies for melanoma].
Kiniwa Y; Okuyama R
Nihon Rinsho; 2012 Dec; 70(12):2172-6. PubMed ID: 23259392
[TBL] [Abstract][Full Text] [Related]
32. Single versus combination immunotherapy drug treatment in melanoma.
Grimaldi AM; Marincola FM; Ascierto PA
Expert Opin Biol Ther; 2016; 16(4):433-41. PubMed ID: 26642234
[TBL] [Abstract][Full Text] [Related]
33. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Wolchok JD; Hodi FS; Weber JS; Allison JP; Urba WJ; Robert C; O'Day SJ; Hoos A; Humphrey R; Berman DM; Lonberg N; Korman AJ
Ann N Y Acad Sci; 2013 Jul; 1291(1):1-13. PubMed ID: 23772560
[TBL] [Abstract][Full Text] [Related]
34. Cancer immunology and melanoma immunotherapy.
Linck RDM; Costa RLP; Garicochea B
An Bras Dermatol; 2017; 92(6):830-835. PubMed ID: 29364441
[TBL] [Abstract][Full Text] [Related]
35. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
Patel SP; Woodman SE
Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for malignant melanoma.
Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F
Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580
[TBL] [Abstract][Full Text] [Related]
37. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
38. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
Simeone E; Ascierto PA
J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
[TBL] [Abstract][Full Text] [Related]
39. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
Kitano S; Tsuji T; Liu C; Hirschhorn-Cymerman D; Kyi C; Mu Z; Allison JP; Gnjatic S; Yuan JD; Wolchok JD
Cancer Immunol Res; 2013 Oct; 1(4):235-44. PubMed ID: 24396833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]